A novel ROCK inhibitor: off-target effects of metformin
Turkish Journal of Biology (2021)
Institution: Gazi University, Turkey
Cell Line: HeLa and MCF-7 (HeLa - cervical cancer cell line; MCF-7 breast cancer cell line)
Research Area: Drug activity
Conclusions: Drug discovery and approval is a lengthy process. Thus in recent years, already approved drugs are tested against nontarget treatments. In this study, A. Özdemir with colleagues have tested two small molecules, metformin and tolbutamide, as Rho kinase (ROCK) inhibitors. Authors have shown that metformin has a potential as a ROCK inhibitor and could be used in treatments of various pathological conditions in which ROCK plays a role. HoloMonitor M4 was used to study cell morphology (cell area, thickness, volume, and irregularity) post-treatment with various concentrations of tolbutamide and metformin.